
doi: 10.3205/16bbag51
Hintergrund: Iluvien® (Fluocinolon Acetonide) ist als second line Therapie seit 2013 bei chronischem DMÖ, das auf andere verfügbare Therapien unzureichend anspricht, zugelassen. Methoden: Retrospektive Fallserie aller seit 2013 in unserer Klinik mit Iluvien® behandelten Augen [zum vollständigen Text gelangen Sie über die oben angegebene URL]
Wintertagung der Berlin-Brandenburgischen Augenärztlichen Gesellschaft 2016
ddc: 610, 610 Medical sciences; Medicine
ddc: 610, 610 Medical sciences; Medicine
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
